These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 32296504)

  • 1. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
    J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
    Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
    Aliment Pharmacol Ther; 2024 Jul; 60(2):201-211. PubMed ID: 38695095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
    J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
    Wong YJ; Thurairajah PH; Kumar R; Tan J; Fock KM; Law NM; Li W; Kwek A; Tan YB; Koh J; Lee ZC; Kumar LS; Teo EK; Ang TL
    J Gastroenterol Hepatol; 2021 May; 36(5):1300-1308. PubMed ID: 33217040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis.
    Zhuang L; Li J; Zhang Y; Ji S; Li Y; Zhao Y; Li B; Li W; Quan M; Duan Y; Zhao H; Cheng D; Wang X; Ou W; Xing H
    Ann Hepatol; 2021; 23():100268. PubMed ID: 33059055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
    Soria A; Fava M; Bernasconi DP; Lapadula G; Colella E; Valsecchi MG; Migliorino GM; D'Ambrosio R; Landonio S; Schiavini M; Spinetti A; Carriero C; Degasperi E; Cologni G; Gatti F; Viganò P; Hasson H; Uberti-Foppa C; Pasulo L; Baiguera C; Rossotti R; Vinci M; Puoti M; Giorgini A; Menzaghi B; Lombardi A; Pan A; Aghemo A; Grossi PA; Boldizzoni R; Colombo S; Viganò M; Rumi MG; Del Poggio P; Valenti L; Giglio O; De Bona A; d'Arminio Monforte A; Colombo A; Spinelli O; Pigozzi MG; Molteni C; Bonfanti P; Terreni N; Perini P; Capretti A; Bella D; Liani C; Polo S; Aimo G; Pagnucco L; Bhoori S; Centenaro R; Graffeo M; Ciaccio A; Dionigi E; Lazzaroni S; Carderi I; Di Marco M; Rizzardini G; Noventa F; Lampertico P; Fagiuoli S
    Liver Int; 2020 Apr; 40(4):769-777. PubMed ID: 31970845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
    Nonomura A; Tamori A; Hai H; Kozuka R; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Intern Med; 2021 Nov; 60(21):3441-3445. PubMed ID: 34024853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
    Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
    J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
    Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
    J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
    Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
    Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
    von Felden J; Vermehren J; Ingiliz P; Mauss S; Lutz T; Simon KG; Busch HW; Baumgarten A; Schewe K; Hueppe D; Boesecke C; Rockstroh JK; Daeumer M; Luebke N; Timm J; Schulze Zur Wiesch J; Sarrazin C; Christensen S
    Aliment Pharmacol Ther; 2018 May; 47(9):1288-1295. PubMed ID: 29536554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis.
    Indolfi G; Easterbrook P; Giometto S; Malik F; Chou R; Lucenteforte E
    Liver Int; 2024 Mar; 44(3):663-681. PubMed ID: 38293756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection.
    Liu CH; Sun HY; Liu CJ; Sheng WH; Hsieh SM; Lo YC; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1690-1698. PubMed ID: 29665069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.